secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001725160-23-000195
Event type: earnings
Sentiment:  positive
Materiality: 0.78
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis Q3: azenosertib 37% ORR, $517M cash, NDA on track for 2026
-------------------------------------------------------------------

- Azenosertib monotherapy achieved 37% ORR and 6.5-month mPFS in heavily pretreated ovarian/uterine serous carcinoma.
- Cash, equivalents & marketable securities of $516.6M as of Sept 30, 2023; projected runway into 2026.
- First NDA for azenosertib targeted in 2026 for a gynecologic malignancy; numerous trials ongoing.
- Mark Lackner, Ph.D., to succeed co-founder Kevin Bunker, Ph.D., as Chief Scientific Officer at year-end.
- ZN-d5 development in AL amyloidosis discontinued to focus resources on azenosertib franchise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516023000195/0001725160-23-000195-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516023000195/zntl-20231106.htm
  HTML page:      https://secwatch.observer/filing/0001725160-23-000195

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer